A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers

Trial Profile

A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms EAGLE-I-13
  • Sponsors Hanwha Chemical
  • Most Recent Events

    • 12 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 12 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top